Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma

Pediatric Blood and Cancer

Volumn 56, Issue 3, 2011, Pages 491-494

  Aguilera, Dolly G ^a   Goldman, Steward ^b   Fangusaro, Jason ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bevacizumab; Irinotecan; Medulloblastoma; Recurrent

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

ALOPECIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHILD; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; MALE; MEDULLOBLASTOMA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 78651096342     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22868     Document Type: Article

References (19)

1. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-4208.
2. Dhall G. Medulloblastoma. J Child Neurol 2009; 24: 1418-1430.
3. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820.
4. Dunkel IJ, Gardner SL, Garvin JH, Jr., et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-Oncol 2010; 12: 297-303.
5. Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer 2010; 54: 649-651.
6. Summers J, Cohen MH, Keegan P, et al. FDA drug approval summary: Bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010; 15: 104-111.
7. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131-1138.
8. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
9. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-316.
10. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7: 1152-1160.
11. Vredenburgh JJ, Desjardins A, Herndon JE, II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259.
12. Huber H, Eggert A, Janss AJ, et al. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 2001; 37: 2064-2072.
13. Ozer E, Sarialioglu F, Cetingoz R, et al. Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: A pediatric oncology group study. Pathol Res Pract 2004; 200: 501-509.
14. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069-3075.
15. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791-795.
16. Privitera G, Acquaviva G, Ettorre GC, et al. Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: Case report and review of the literature. J Oncol 2009; 2009: 247873.
17. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008; 26: 271-278.
18. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009; 69: 5296-5300.
19. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007; 25: 4714-4721.